[Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].

Autor:	Plander M; Vas Megyei Markusovszky Kórház, Egyetemi Oktatókórház Nonprofit Zrt. Haematologiai és Haemostaseologiai Osztály, Szombathely. planderm@yahoo.com, Skrapits J, Bozsó T, Szendrei T, Iványi JL
Jazyk:	maďarština
Zdroj:	Orvosi hetilap [Orv Hetil] 2012 Oct 14; Vol. 153 (41), pp. 1622-8.
DOI:	10.1556/OH.2012.29458
Abstrakt:	Introduction: Minimal residual disease is associated with longer overall survival in patients with chronic lymphocytic leukemia. Aim: The aim of the authors was to determine the clinical significance of remission and minimal residual disease on the survival of patients with chronic lymphocytic leukemia. Methods: Data from 42 first-line treated patients with chronic lymphocytic leukemia were analyzed. Minimal residual disease was determined by flow cytometry. Results: Overall response and complete remission was achieved in 91%, 86%, 100% and 87%, 0%, 60% of patients with fludarabine-based combinations, single-agent fludarabine and cyclophosphamide + vincristin + prednisolone regimen, respectively. Minimal residual disease eradication was feasible only with fludarabine-based combinations in 60% of these cases. The ratio of minimal residual disease was 0.5% on average. During a median follow-up period lasting 30 months, the overall survival of patients with fludarabine-resistant disease proved to be significantly shorter (p = 0.04), while complete remission without minimal residual disease was associated with significantly longer progression free survival (p = 0.02). Conclusion: Only fludarabine-based combinations were able to eradicate minimal residual disease in patients with chronic lymphocytic leukemia. Complete remission without minimal residual disease may predict longer progression free survival in these patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu